Sangamo Biosciences Inc (SGMO)

[georgie18]

SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.